Conference Presentation
The Impact of Dual vs Single Anti-HER2: A Real-World Retrospective Analysis of Treatment Outcome in Bangladesh
Presented at 15TH EUROPEAN BREAST CANCER CONFERENCE on March 25, 2026
Presentation Abstract
Background
The integration of dual HER2 blockade (trastuzumab + pertuzumab, PH) has improved outcomes in HER2-positive breast cancer, particularly in neoadjuvant and metastatic settings. However, evidence from routine clinical practice in low- and middle-income countries is limited. This study aimed to evaluate real-world survival outcomes, response rates, and safety of dual versus single blockade (trastuzumab alone, H) across treatment settings.
Target Audience
https://event.eortc.org/ebcc15/
Event Location
Spain, Barcelona